MEDICATION SAFETY ISSUES
Sound-alike/look-alike issues:
AmLODIPine may be confused with aMILoride
Norvasc® may be confused with Navane®, Norvir®, Vascor®
U.S. BRAND NAMES — Norvasc®
PHARMACOLOGIC CATEGORY
Calcium Channel Blocker
Calcium Channel Blocker, Dihydropyridine
DOSING: ADULTS
Hypertension: Oral: Initial dose: 5 mg once daily; maximum dose: 10 mg once daily. In general, titrate in 2.5 mg increments over 7-14 days. Usual dosage range (JNC 7): 2.5-10 mg once daily.
Angina: Oral: Usual dose: 5-10 mg; lower dose suggested in elderly or hepatic impairment; most patients require 10 mg for adequate effect.
DOSING: PEDIATRIC — Hypertension: Oral: Children 6-17 years: 2.5-5 mg once daily
(For additional information see "Amlodipine: Pediatric drug information")
DOSING: ELDERLY — Dosing should start at the lower end of dosing range due to possible increased incidence of hepatic, renal, or cardiac impairment. Elderly patients also show decreased clearance of amlodipine.
Hypertension: Oral: 2.5 mg once daily
Angina: Oral: 5 mg once daily
DOSING: RENAL IMPAIRMENT — Dialysis: Hemodialysis and peritoneal dialysis do not enhance elimination. Supplemental dose is not necessary.
DOSING: HEPATIC IMPAIRMENT
Hypertension: Administer 2.5 mg once daily
Angina: Administer 5 mg once daily
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Tablet: 2.5 mg, 5 mg, 10 mg
Norvasc®: 2.5 mg, 5 mg, 10 mg
DOSAGE FORMS: CONCISE
Tablet: 2.5 mg, 5 mg, 10 mg
Norvasc®: 2.5 mg, 5 mg, 10 mg
GENERIC EQUIVALENT AVAILABLE — Yes
ADMINISTRATION — May be administered without regard to meals.
USE — Treatment of hypertension; treatment of symptomatic chronic stable angina, vasospastic (Prinzmetal's) angina (confirmed or suspected); prevention of hospitalization due to angina with documented CAD (limited to patients without heart failure or ejection fraction <40%)>10%: Cardiovascular: Peripheral edema (2% to 15% dose related)
1% to 10%:
Cardiovascular: Flushing (1% to 3%), palpitation (1% to 4%)
Central nervous system: Headache (7%; similar to placebo 8%), dizziness (1% to 3%), fatigue (4%), somnolence (1% to 2%)
Dermatologic: Rash (1% to 2%), pruritus (1% to 2%)
Endocrine & metabolic: Male sexual dysfunction (1% to 2%)
Gastrointestinal: Nausea (3%), abdominal pain (1% to 2%), dyspepsia (1% to 2%), gingival hyperplasia
Neuromuscular & skeletal: Muscle cramps (1% to 2%), weakness (1% to 2%)
Respiratory: Dyspnea (1% to 2%), pulmonary edema (15% from PRAISE trial, CHF population)
<1%>90%) to inactive metabolite
Bioavailability: 64% to 90%
Half-life elimination: 30-50 hours; increased with hepatic dysfunction
Time to peak, plasma: 6-12 hours
Excretion: Urine (10% as parent, 60% as metabolite)
PATIENT INFORMATION — Take as prescribed; do not stop abruptly without consulting prescriber. You may experience headache (if unrelieved, consult prescriber), nausea or vomiting (frequent small meals may help), or constipation (increased dietary bulk and fluids may help). May cause drowsiness; use caution when driving or engaging in tasks that require alertness until response to drug is known. Report unrelieved headache, vomiting, constipation, palpitations, peripheral or facial swelling, weight gain >5 lb/week, or respiratory changes.
Here You can search All About Health,Pharma,Medicine,A Thounds Articles and Medicine Pharma-Guide: Provides diverse and comprehensive data & information which can be helpful to the Pharmaceutical profession. Pharma-Guide: Provides the Country/Category wise Directory, the trade center, Bulk Drug Prices, details various exhibitions conducted from time to time worldwide. Pharma-Guide: Is a leader, promoting the industries in the global market.
Sunday, August 1, 2010
Subscribe to:
Post Comments (Atom)
Infomed Drug Guide
The information contained in the "Infomed Drug Guide" is aimed at medical professionals and students of medicine and pharmacology. All of the data has been carefully compiled and checked, however, errors may occur. These errors may also result due to changes that have taken place in the medical sciences since the publication of the Drug Guide in 1994/2008, and cannot be excluded. In case of doubt, readers are encouraged to confirm the information contained herein with other sources before a drug is prescribed. Non-professionals should be aware that the "Infomed Drug Guide" does not seek to replace professional medical advice and/or treatment. Neither Infomed, nor the authors, claim that the information is in every respect accurate or complete. As a result, neither can be held responsible for any errors or omissions, or for any consequences resulting from the use of such information.
No comments:
Post a Comment